Announcements Trials
Browse Landscape

Status

Completed 456Recruiting 171Terminated 169Active not recruiting 83Unknown 62Not yet recruiting 28Withdrawn 22Suspended 5Available 3No longer available 2Enrolling by invitation 2Approved for marketing 2Temporarily not available 1

Sponsor Class

INDUSTRY 2

Study Type

Expanded_access 2

Sponsor

Cancer Type

Gynecologic 2Gastrointestinal 2Thoracic 1Sarcoma 1Genitourinary 1Dermatologic 1Breast 1

Conditions

Multiple Myeloma 15Melanoma 14Carcinoma, Non-Small-Cell Lung 13Recurrence 12Neoplasms 12Leukemia, Myeloid, Acute 9Glioblastoma 8Prostatic Neoplasms 6Lung Neoplasms 6Breast Neoplasms 6Lymphoma 5Glioma 5Carcinoma, Renal Cell 5Sarcoma 4Pancreatic Neoplasms 4Lymphoma, Non-Hodgkin 4Gastrointestinal Stromal Tumors 4Colorectal Neoplasms 4Triple Negative Breast Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Carcinoma 3Solid Tumors 2Small Cell Lung Carcinoma 2Ovarian Neoplasms 2Neoplasms by Site 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Large-Cell, Anaplastic 2Liver Neoplasms 2Leukemia 2

Interventions

pegilodecakin 1AM0010 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
No longer available × INDUSTRY × Ovarian Neoplasms × Clear all
NCT04681248 2025-08-03

Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors

Leap Therapeutics, Inc.

No longer available
GastrointestinalGynecologicSarcoma

Carcinoma, Squamous Cell, Carcinosarcoma, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Uterine Neoplasms, Endometrial Neoplasms

NCT03554434 2020-03-02

An Expanded Access Program for AM0010 (Pegilodecakin)

Eli Lilly and Company

No longer available
BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡